The purpose of this study is to find out whether giving a drug called PCK3145 can reduce the
level of a protein in the blood called MMP-9 as well as to find out how long the drug will
remain in your system over time. This drug has been tested previously in prostate cancer
patients abroad and has been shown to be safe with minimal side effects. However, we do not
know whether changes in MMP-9 levels correlate with tumor shrinkage or symptom improvement.
We would also like to evaluate the potential pain relief (analgesic) effect of PCK3145 at
15mg/m² i.v. weekly for 12 weeks on patients with both symptomatic and asymptomatic castrate
metastatic prostate cancer who are dependent on opioid analgesics. We would also like to
monitor pain through a brief pain questionaire, and determine the impact on markers of bone
- Patients who have castrate metastatic prostate cancers are eligible based on the
- Patients with prostate cancer must have castrate metastatic disease (i.e. disease
progression following castration or treatment with a gonadotropin releasing hormone
analog. Patients with prostate cancer may have progressing metastatic disease on
imaging studies (bone scan, CT scan or MRI) in addition to a rising PSA.
- Biochemical progression will be defined as: A minimum of three rising PSA values from
a baseline that are obtained 1 week or more apart, or two rising PSA values more than
one month apart, where the percentage increase over the range of values is at least
- Maintaining castrate status: Patients who have not undergone surgical orchiectomy
should continue on medical therapies [i.e. gonadotropin releasing hormone analogs] to
maintain castrate levels of serum testosterone. Patients who are receiving an
anti-androgen as part of first line hormonal therapy must have shown progression of
disease off the anti-androgen prior to enrollment.
- Histologically confirmed diagnosis of prostate cancer per MSKCC review.
- No limitations on the duration of or number of prior therapies.
- Age ≥ 18 years
- Karnofsky performance status ≥ 70% (ECOG ≤ 1.0).
- Life expectancy of greater than 6 months.
- Hematologic: WBC ≥ 3000K/μl.
- Absolute neutrophil count ≥ 1500 K/μl
- Platelet count ≥ 100,000 K/μl.
- Hepatic: Total Bilirubin - within normal institutional limits
- AST < 1.5 x ULN, ALT < 1.5 x ULN.
- Renal: Creatinine < 2.0 or creatinine clearance > 55 mL/min
- Coagulation: Prothrombin time - Less than or equal to the ULN (upper limit of normal)
unless patient is taking anticoagulants
- Patients must have recovered from the acute toxicities of any prior therapy, and not
received chemotherapy, radiation therapy or other investigational anticancer
therapeutic drugs for at least 4 weeks prior to entry.
- Ability to understand and the willingness to sign a written informed consent
- Testosterone < 50 ng/dl
- Patients may be symptomatic and must be dependent on opioid analgesics or
nonsteroidal anti-inflammatory drugs
- Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering
the study or those who have not recovered from the adverse events due to agents
administered more than 4 weeks earlier.
- Patients may not be receiving any other investigational agents.
- Patients with active brain metastases or epidural disease
- Uncontrolled intercurrent illness including but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
- No current therapy with alternative/complementary drugs such as PC Plus, saw palmetto
- No rectal bleeding except that seen following radiation proctitis or known history of
- Non-prostate primary carcinoma except for non-melanoma skin cancer within previous 5
- No uncontrolled cardiac arrhythmias.
- Patient taking steroids for cord compression or pain control are excluded. Patient on
steroids for chronic conditions such as arthritis or asthma or on chronic
hydrocortisone post ketoconazole will be permitted.